RED:NICE TA924 - Tirzepatide for treating type 2 diabetes. RED recommendation as holding position for TA compliance. ICB commissioned (Decision date November 2023)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care